G-CSF-mobilized peripheral blood mononuclear cells added to marrow facilitates engraftment in nonmyeloablated canine recipients: CD3 cells are required.
暂无分享,去创建一个
R. Storb | B. Storer | J. Zaucha | B. Torok-Storb | G. Georges | E. Zellmer | M. Little
[1] R Storb,et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. , 2001, The New England journal of medicine.
[2] C. Perreault,et al. Immunobiology of allogeneic peripheral blood mononuclear cells mobilized with granulocyte-colony stimulating factor , 2000, Bone Marrow Transplantation.
[3] N. Schmitz,et al. Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. IBMTR Histocompatibility and Stem Cell Sources Working Committee and the European Group for Blood and Marrow Transplantation (EBMT). , 2000, Blood.
[4] N. Young,et al. Pharmacologic doses of granulocyte colony-stimulating factor affect cytokine production by lymphocytes in vitro and in vivo. , 2000, Blood.
[5] J. Bourhis,et al. Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia: a report from the Société Française de Greffe de Moelle. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] S. Lonial,et al. Irradiated donor leukocytes promote engraftment of allogeneic bone marrow in major histocompatibility complex mismatched recipients without causing graft-versus-host disease. , 1999, Blood.
[7] N. Hensel,et al. Human G‐CSF‐mobilized CD34‐positive peripheral blood progenitor cells can stimulate allogeneic T‐cell responses: implications for graft rejection in mismatched transplantation , 1999, British journal of haematology.
[8] M. Álvarez-Mon,et al. Granulocyte colony-stimulating factor (G-CSF) transiently suppresses mitogen-stimulated T-cell proliferative response , 1999, British Journal of Cancer.
[9] J. Talmadge,et al. Comparison of monocyte-dependent T cell inhibitory activity in GM-CSF vs G-CSF mobilized PSC products , 1999, Bone Marrow Transplantation.
[10] B. Sandmaier,et al. The expression and differentiation pattern of cell antigens and adhesion molecules on the nonadherent cell population in canine long-term marrow culture: a biphasic development of myeloid and lymphoid cells. , 2008, Tissue antigens.
[11] R. Storb,et al. Canine T cells transduced with a herpes simplex virus thymidine kinase gene: a model to study effects on engraftment and control of graft-versus-host disease. , 1998, Transplantation.
[12] M. Mielcarek,et al. Production of interleukin-10 by granulocyte colony-stimulating factor-mobilized blood products: a mechanism for monocyte-mediated suppression of T-cell proliferation. , 1998, Blood.
[13] P. Chrobak,et al. Non-host-reactive donor CD8+ T cells of Tc2 phenotype potently inhibit marrow graft rejection. , 1998, Blood.
[14] R. Storb,et al. Characterization of monoclonal antibodies that recognize canine CD34. , 1998, Blood.
[15] M. Mielcarek,et al. Impaired induction of the CD28-responsive complex in granulocyte colony-stimulating factor mobilized CD4 T cells. , 1998, Blood.
[16] S. Strober,et al. Granulocyte colony-stimulating factor reduces the capacity of blood mononuclear cells to induce graft-versus-host disease: impact on blood progenitor cell transplantation. , 1997, Blood.
[17] H. Deeg,et al. Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. , 1997, Blood.
[18] R. Negrin,et al. Granulocyte colony-stimulating factor-induced comobilization of CD4- CD8- T cells and hematopoietic progenitor cells (CD34+) in the blood of normal donors. , 1997, Blood.
[19] M. Mielcarek,et al. Suppression of alloantigen-induced T-cell proliferation by CD14+ cells derived from granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cells. , 1997, Blood.
[20] R. Storb,et al. Molecular analysis of DLA-DRBB1 polymorphism. , 1996, Tissue antigens.
[21] R. Storb,et al. Allogeneic peripheral blood stem cell transplantation in patients with advanced hematologic malignancies: a retrospective comparison with marrow transplantation. , 1996, Blood.
[22] E. Ostrander,et al. Histocompatibility testing of dog families with highly polymorphic microsatellite markers. , 1996, Transplantation.
[23] H. Deeg,et al. Allogeneic transplants of canine peripheral blood stem cells mobilized by recombinant canine hematopoietic growth factors , 1996 .
[24] J. Ferrara,et al. Pretreatment of donor mice with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward type-2 cytokine production and reduces severity of experimental graft-versus-host disease. , 1995, Blood.
[25] H. Deeg,et al. DLA-identical marrow grafts after low-dose total-body irradiation. Addition of viable donor peripheral blood mononuclear cells does not enhance engraftment. , 1995, Transplantation.
[26] N. Schmitz,et al. Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (granulocyte colony-stimulating factor) , 1995, Blood.
[27] Giralt,et al. Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: potential advantage of blood over marrow allografts. , 1995, Blood.
[28] E. Bryant,et al. USE OF (CA)n POLYMORPHISMS TO DETERMINE THE ORIGIN OF BLOOD CELLS AFTER ALLOGENEIC CANINE MARROW GRAFTING , 1994, Transplantation.
[29] P. Martin,et al. Donor CD8 cells prevent allogeneic marrow graft rejection in mice: potential implications for marrow transplantation in humans , 1993, The Journal of experimental medicine.
[30] F. Appelbaum,et al. STUDIES OF THE USE OF L‐LEUCYL‐L‐LEUCINE METHYL ESTER IN CANINE ALLOGENEIC MARROW TRANSPLANTATION , 1993, Transplantation.
[31] H. Deeg,et al. Marrow toxicity of fractionated vs. single dose total body irradiation is identical in a canine model. , 1993, International journal of radiation oncology, biology, physics.
[32] P. Martin. The role of donor lymphoid cells in allogeneic marrow engraftment. , 1990, Bone marrow transplantation.
[33] L. Shaw,et al. Consensus document: Hawk's Cay meeting on therapeutic drug monitoring of cyclosporine. , 1990, Transplantation proceedings.
[34] T. Lapidot,et al. Enhancement of bone marrow allografts from nude mice into mismatched recipients by T cells void of graft-versus-host activity. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[35] L. Shaw,et al. Consensus document: Hawk's Cay meeting on therapeutic drug monitoring of cyclosporine. , 1990, Clinical chemistry.
[36] W. Ladiges. 4 – Experimental Techniques Used to Study the Immune System of Dogs and Other Large Animals , 1989 .
[37] B. Sandmaier,et al. L-leucyl-L-leucine methyl ester treatment of canine marrow and peripheral blood cells. Inhibition of proliferative responses with maintenance of the capacity for autologous marrow engraftment. , 1988, Transplantation.
[38] H. Deeg,et al. Graft failure in patients receiving T cell-depleted HLA-identical allogeneic marrow transplants. , 1988, Bone marrow transplantation.
[39] J. Gribben,et al. Graft rejection following HLA matched T‐lymphocyte depleted bone marrow transplantation , 1986, British journal of haematology.
[40] J. Heavner. Methods of animal experimentation , 1965 .